ROSEN, A LEADING LAW FIRM, Encourages Orphazyme A/S Investors With Losses Over $100K to Secure Counsel Before Important September 7 Deadline in Securities Class Action – ORPH
August 03, 2021 16:04 ET
|
The Rosen Law Firm PA
NEW YORK, Aug. 03, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or...
Biotalys Nominates Catherine Moukheibir to its Board of Directors
June 10, 2021 02:00 ET
|
Biotalys
Ghent, BELGIUM, June 10, 2021 (GLOBE NEWSWIRE) -- Biotalys Nominates Catherine Moukheibir to its Board of Directors Highly respected finance and life sciences professional to chair company’s Audit...
Orphazyme to prepare for filing of arimoclomol in US for Niemann-Pick disease Type C (NPC)
July 21, 2019 06:03 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 18/2019Company Registration No. 32266355 ...
Orphazyme completes enrollment in phase 3 trial evaluating arimoclomol in Amyotrophic Lateral Sclerosis
July 18, 2019 01:00 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 17/2019 ...
Orphazyme to prepare for filing of arimoclomol in Europe for Niemann-Pick disease Type C (NPC)
June 07, 2019 00:56 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Orphazyme announces enrollment of first patient in Phase III clinical trial of arimoclomol for ALS
August 10, 2018 12:19 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Orphazyme assumes sponsorship of Phase II/III sIBM trial
December 15, 2017 09:20 ET
|
ORPHAZYME A/S
Investor newsNo. 01/2017 Orphazyme assumes sponsorship of Phase II/III sIBM trial On December 14, 2017, Orphazyme A/S, University of Kansas Medical Center, and UCL announced that Orphazyme...